Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia
CA 2467781 C · Owner: Freedman, John · Inventors: Lazarus, Alan H.; Freedman, John; Crow, Andrew R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates monoclonal antibodies specific for a red blood cell and capable of inhibiting the reticuloendothelial system for the treatment of idiopathic thrombocytopenic purpura (ITP) as well as for the reduction of platelet clearance. Related pharmaceutical composition and uses are also provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 20, 2001 and granted September 23, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 20, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 20, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.